Cytosorbents Corporation (CTSO)

Market Cap	30.10M -42.5%
Revenue (ttm)	37.20M +5.3%
Net Income	-11.85M
EPS	-0.19
Shares Out	62.70M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,738
Open	0.4830
Previous Close	0.4679
Day's Range	0.4549 - 0.4900
52-Week Range	0.4350 - 1.3900
Beta	1.44
Analysts	Hold
Price Target	2.88 (+500.0%)
Earnings Date	May 13, 2026

About CTSO

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammator...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1997
• Employees: 129
• Stock Exchange: NASDAQ
• Ticker Symbol: CTSO
• Website: https://www.cytosorbents.com

Financial Performance

In 2025, Cytosorbents's revenue was $37.06 million, an increase of 4.12% compared to the previous year's $35.60 million. Losses were -$8.20 million, -60.43% less than in 2024.

Analyst Summary

According to one analyst, the rating for CTSO stock is "Hold" and the 12-month stock price target is $2.88.

Price Target

$2.88

(500.00% upside)

Analyst Consensus: Hold